Mereo BioPharma Completes Type B End-of-Phase 2 Meeting with FDA and Agrees on Pivotal Phase 3 Pediatric Study Design for Setrusumab in Osteogenesis Imperfecta

Mereo Biopharma announced the successful completion of a Type B End-of-Phase 2 meeting with the U.S. FDA to discuss the development of setrusumab, an anti-sclerostin antibody, for the treatment of children and adolescents with osteogenesis imperfecta (OI). During the...

Pin It on Pinterest